A role for destabilizing amino acid replacements in light-chain amyloidosis.
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Light-chain (L-chain) amyloidosis is characterized by deposition of fibrillar aggregates composed of the N-terminal L-chain variable region (VL) domain of an immunoglobulin, generally in individuals overproducing a monoclonal L chain. In addition to proteolytic fragmentation and high protein concentration, particular amino acid substitutions may also contribute to the tendency of an L chain to aggregate in L-chain amyloidosis, although evidence in support of this has been limited and difficult to interpret. In this paper we identify particular amino acid replacements at specific positions in the VL domain that are occupied at frequencies significantly higher in those L chains associated with amyloidosis. Analysis of the structural model for the VL domain of the Bence-Jones protein REI suggests that these positions play important roles in maintaining domain structure and stability. Using an Escherichia coli expression system, we prepared single-point mutants of REI VL incorporating amyloid-associated amino acid replacements that are both rare and located at structurally important positions. These mutants support ordered aggregate formation in an in vitro L-chain fibril formation model in which wild-type REI VL remains soluble. Moreover, the ability of these sequences to aggregate in vitro correlates well with the extent to which domain stability is decreased in denaturant-induced unfolding. The results are consistent with a mechanism for the disease process in which the VL domain, either before or after proteolytic cleavage from the L-chain constant region domain, unfolds by virtue of one or more destabilizing amino acid replacements to generate an aggregation-prone nonnative state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Santoro, M. M., & Bolen, D. W. (1988) · Biochemistry · doi:10.1021/bi00421a014 · Cited by 1,582
Mutation of the Alzheimer's Disease Amyloid Gene in Hereditary Cerebral Hemorrhage, Dutch Type
Levy, E., Carman, M. D., Fernandez-Madrid, I. J., Power, M. D., Lieberburg, I., van Duinen, S. G., Bots, G. T. A. M., Luyendijk, W., & Frangione, B. (1990) · Science · doi:10.1126/science.2111584 · Cited by 1,381
Haass, C., Koo, E. H., Mellon, A., Hung, A. Y., & Selkoe, D. J. (1992) · Nature · doi:10.1038/357500a0 · Cited by 899
Klunk, W. E., Pettegrew, J. W., & Abraham, D. J. (1989) · Journal of Histochemistry & Cytochemistry · doi:10.1177/37.8.2666510 · Cited by 623
Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro
Colon, W., & Kelly, J. W. (1992) · Biochemistry · doi:10.1021/bi00151a036 · Cited by 573
Potentially Amyloidogenic, Carboxyl-Terminal Derivatives of the Amyloid Protein Precursor
Estus, S., Golde, T. E., Kunishita, T., Blades, D., Lowery, D., Eisen, M., Usiak, M., Qu, X., Tabira, T., Greenberg, B. D., et al. (1992) · Science · doi:10.1126/science.1738846 · Cited by 431
Creation of "Amyloid" Fibrils from Bence Jones Proteins in vitro
Glenner, G. G., Ein, D., Eanes, E. D., Bladen, H. A., Terry, W., & Page, D. L. (1971) · Science · doi:10.1126/science.174.4010.712 · Cited by 377
Genetic and structural analysis of the protein stability problem
Matthews, B. W. (1987) · Biochemistry · doi:10.1021/bi00396a001 · Cited by 222
McCutchen, S. L., Colon, W., & Kelly, J. W. (1993) · Biochemistry · doi:10.1021/bi00096a024 · Cited by 197
[26] Effect of point mutations of the folding of globular proteins
Matthews, C. R. (1987) · Methods in Enzymology · doi:10.1016/0076-6879(87)54092-7 · Cited by 190
Cited by
Molecular Mechanisms of Amyloidosis
Merlini, G., & Bellotti, V. (2003) · New England Journal of Medicine · doi:10.1056/nejmra023144 · Cited by 1,920
Falk, R. H., Comenzo, R. L., & Skinner, M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199709253371306 · Cited by 1,180
Protein aggregation: folding aggregates, inclusion bodies and amyloid
Fink, A. L. (1998) · Folding and Design · doi:10.1016/s1359-0278(98)00002-9 · Cited by 1,157
Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis
Booth, D. R., Sunde, M., Bellotti, V., Robinson, C. V., Hutchinson, W. L., Fraser, P. E., Hawkins, P. N., Dobson, C. M., Radford, S. E., Blake, C. C. F., et al. (1997) · Nature · doi:10.1038/385787a0 · Cited by 1,048
Conformational constraints for amyloid fibrillation: the importance of being unfolded
Uversky, V. N., & Fink, A. L. (2004) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2003.12.008 · Cited by 1,015
The alternative conformations of amyloidogenic proteins and their multi-step assembly pathways
Kelly, J. W. (1998) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(98)80016-x · Cited by 1,001
Identifying the amylome, proteins capable of forming amyloid-like fibrils
Goldschmidt, L., Teng, P. K., Riek, R., & Eisenberg, D. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915166107 · Cited by 809
Hamley, I. W. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200700861 · Cited by 618
Stability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616
Characterization and Dynamics of Aggresome Formation by a Cytosolic Gfp-Chimera✪
García-Mata, R., Bebök, Z., Sorscher, E. J., & Sztul, E. S. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.6.1239 · Cited by 595
Alternative conformations of amyloidogenic proteins govern their behavior
Kelly, J. W. (1996) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(96)80089-3 · Cited by 593
Pawar, A. P., DuBay, K. F., Zurdo, J., Chiti, F., Vendruscolo, M., & Dobson, C. M. (2005) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.04.016 · Cited by 588
Structural Insights into the Evolution of an Antibody Combining Site
Wedemayer, G. J., Patten, P. A., Wang, L. H., Schultz, P. G., & Stevens, R. C. (1997) · Science · doi:10.1126/science.276.5319.1665 · Cited by 546
Kinetic partitioning of protein folding and aggregation
Chiti, F., Taddei, N., Baroni, F., Capanni, C., Stefani, M., Ramponi, G., & Dobson, C. M. (2002) · Nature Structural Biology · doi:10.1038/nsb752 · Cited by 422
Targeting protein aggregation for the treatment of degenerative diseases
Eisele, Y. S., Monteiro, C., Fearns, C., Encalada, S. E., Wiseman, R. L., Powers, E. T., & Kelly, J. W. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4593 · Cited by 419
Hassles with Taking Out the Garbage: Aggravating Aggresomes
Garcia‐Mata, R., Gao, Y., & Sztul, E. (2002) · Traffic · doi:10.1034/j.1600-0854.2002.30602.x · Cited by 391
Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity
Hammarström, P., Jiang, X., Hurshman, A. R., Powers, E. T., & Kelly, J. W. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.202495199 · Cited by 359
Inhibiting transthyretin amyloid fibril formation via protein stabilization
Miroy, G. J., Lai, Z., Lashuel, H. A., Peterson, S. A., Strang, C., & Kelly, J. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.26.15051 · Cited by 344
The protofilament substructure of amyloid fibrils11Edited by F. E. Cohen
Serpell, L. C., Sunde, M., Benson, M. D., Tennent, G. A., Pepys, M. B., & Fraser, P. E. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3908 · Cited by 342
Johnson, S. M., Connelly, S., Fearns, C., Powers, E. T., & Kelly, J. W. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.060 · Cited by 328
Morozova-Roche, L. A., Zurdo, J., Spencer, A., Noppe, W., Receveur, V., Archer, D. B., Joniau, M., & Dobson, C. M. (2000) · Journal of Structural Biology · doi:10.1006/jsbi.2000.4264 · Cited by 319
Prediction of the Absolute Aggregation Rates of Amyloidogenic Polypeptide Chains
DuBay, K. F., Pawar, A. P., Chiti, F., Zurdo, J., Dobson, C. M., & Vendruscolo, M. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.06.043 · Cited by 318
Prolines and Aamyloidogenicity in Fragments of the Alzheimer's Peptide .beta./A4
Wood, S. J., Wetzel, R., Martin, J. D., & Hurle, M. R. (1995) · Biochemistry · doi:10.1021/bi00003a003 · Cited by 312
Self-citationOligomer Formation By 3D Domain Swapping: A Model For Protein Assembly And Misassembly
SCHLUNEGGER, M., BENNETT, M., & EISENBERG, D. (1997) · Advances in Protein Chemistry · doi:10.1016/s0065-3233(08)60319-8 · Cited by 286
Lashuel, H. A., LaBrenz, S. R., Woo, L., Serpell, L. C., & Kelly, J. W. (2000) · Journal of the American Chemical Society · doi:10.1021/ja9937831 · Cited by 285
Clinical aspects of systemic amyloid diseases
Obici, L., Perfetti, V., Palladini, G., Moratti, R., & Merlini, G. (2005) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2005.08.014 · Cited by 278
Chiti, F., Calamai, M., Taddei, N., Stefani, M., Ramponi, G., & Dobson, C. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212527999 · Cited by 273
Therapeutic strategies for human amyloid diseases
Sacchettini, J. C., & Kelly, J. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd769 · Cited by 261
Horwich, A. (2002) · Journal of Clinical Investigation · doi:10.1172/jci0216781 · Cited by 185
Kad, N. M., Thomson, N. H., Smith, D. P., Smith, D. A., & Radford, S. E. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2001.5071 · Cited by 176
Involvement of cystatin C in pathophysiology of CNS diseases
Nagai, A. (2008) · Frontiers in Bioscience · doi:10.2741/2941 · Cited by 44
“Therefore, there is a tendency to explain amyloidogenity in terms of reduced stability of the proteins (16, 17).”
Background
Metadata
- Authors
- Hurle, M. R., Helms, L. R., Li, L., Chan, W., & Wetzel, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 1994-06-07
- Volume
- 91
- Issue
- 12
- Pages
- 5446-5450
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W1967773653
- Cited by
- 348
- References
- 17
- FWCI
- 3.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.